NeoGenomics(NEO) - 2024 Q4 - Earnings Call Presentation

Financial Performance - Q4 2024 - Revenue increased by 11% to $172 million[46] - Clinical volume grew by 9% to 322,000 units[10, 42] - Adjusted Gross Profit increased by 14% to $83 million[42] - Adjusted EBITDA increased by 27% to $12 million[15, 42] - Clinical NGS revenue grew by 24%[17, 43] Financial Performance - Full Year 2024 - Revenue increased by 12% to $661 million[51, 52] - Adjusted Gross Profit increased by 18% to $311 million[51] - Adjusted EBITDA increased significantly to $40 million, a 1036% increase[51, 52] - Cash flow from operations increased significantly to $7 million, a 460% increase[51] - Clinical NGS revenue grew by 34%[52] Future Outlook - 2025 Guidance - Revenue is projected to be between $735 million and $745 million, representing a year-over-year growth of 11% to 13%[53] - Adjusted EBITDA is projected to be between $55 million and $58 million, representing a year-over-year growth of 38% to 45%[53]